AVIR - Company ID 0001593899
The table below shows Atea Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $351.37M | $48.63M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $148.02M | $144.10M | $114.24M | $81.94M | $167.21M | $38.02M |
| SG&A |
Atea Pharmaceuticals, Inc. reported annual revenue of $351.37M for fiscal year 2021. That is up 622.5% from $48.63M in fiscal 2020. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $32.86M |
| $48.85M |
| $49.92M |
| $48.71M |
| $45.78M |
| $21.64M |
| Operating income | -$180.89M | -$192.95M | -$164.16M | -$130.65M | $138.38M | -$11.03M |
| Income tax | -$6.16M | $925.00K | $1.02M | -$3.59M | $17.40M | - |
| Net income | -$158.00M | -$168.00M | -$136.00M | -$116.00M | $121.00M | -$10.95M |
| EPS (diluted) | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.37 | -$0.51 |